Researchers look back at how doctors treated blood cancer patients
NCT ID NCT07357441
Summary
This study looked back at the medical records of 355 people in Turkey who were treated for myelofibrosis, a type of bone marrow cancer. The goal was to understand the real-world use of the drug ruxolitinib, including patient characteristics, treatment patterns, and side effects. Researchers collected data from 2015 to 2022 to see how the disease was managed in everyday clinical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.